Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
jeudi, novembre 19
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Editas Medicine Inc
EDIT
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$1.77
-0.055
-3.01%
À la clôture: Nov 18, 4:00 PM EST
$1.80
-0.0237
-1.3%
Pré-ouverture: 7:05 AM EST
Get Report
Aperçu
Actualités
Graphiques
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Editas Medicine Financials
Editas Medicine (EDIT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Editas Medicine Q3 EPS $(0.15) Beats $(0.18) Estimate, Sales $10.365M Beat $4.460M Estimate
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.18) by 16.67 percent. This is a 46.43 percent increase over losses of $(0.28) per share from
Benzinga Newsdesk
PRO
Editas Medicine Q2 EPS $(0.15) Beats $(0.27) Estimate, Sales $11.900M Beat $2.800M Estimate
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.27) by 44.44 percent. This is a 76.19 percent increase over losses of $(0.63) per share from
Benzinga Newsdesk
PRO
Editas Medicine Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $2.831M Miss $4.065M Estimate
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 39.53 percent increase over losses of $(0.43) per share from
Benzinga Newsdesk
Editas Medicine Q4 Earnings Assessment
Benzinga Insights
PRO
Editas Medicine Q4 EPS $(0.06) Beats $(0.25) Estimate, Sales $24.741M Beat $5.595M Estimate
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.25) by 76.19 percent. This is a 85 percent increase over losses of $(0.40) per share from the
Benzinga Newsdesk
PRO
Editas Medicine Q3 EPS $(0.28) Beats $(0.29) Estimate, Sales $7.543M Beat $5.020M Estimate
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 5.08 percent. This is a 62.67 percent increase over losses of $(0.75) per share from
Benzinga Newsdesk